@article{APS4345,
author = {Yin Huang and Jing Chen and Ge Li and Tian-yue Cheng and Ming-hong Jiang and Shu-yu Zhang and Jun Lu and Shi Yan and Wei-wei Fan and Da-ru Lu},
title = {Reversal of hyperglycemia by protein transduction of NeuroD in vivo},
journal = {Acta Pharmacologica Sinica},
volume = {28},
number = {8},
year = {2016},
keywords = {},
abstract = {Aim: To test whether the neurogenic differentiation (NeuroD) protein could alleviate symptoms of diabetes mellitus by its transduction activity in vivo.
Methods: Type 1 diabetes mellitus in mice was induced by ip (intraperitoneal) injection of streptozotocin (150 mg/kg). One group of diabetic mice were intravenously injected with the NeuroD-EGFP (Enhanced Green Fluorescent Protein) (5 mg/kg, n= 6) and the other group with EGFP (5 mg/kg, n= 5). After the transduction of NeuroD-EGFP, the distribution of the protein was examined by means of frozen section under fluorescent microscope observation. We conducted RT-PCR and Real-time quantitative PCR to measure the transcription levels of insulin mRNA. Immunohistochemistry was utilized to detect the insulin protein. Radioimmunoassay was conducted to determine the serum insulin levels. Blood glucose levels and body weights were regularly recorded after the protein administration.
Results: The NeuroD protein can be transduced into cells in vivo with a high efficiency of nearly 100%. Insulin mRNA was highly expressed in NeuroD-treated diabetic mice, 38-fold higher than that of control group (P},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/4345}
}